Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study - Aix-Marseille Université Access content directly
Journal Articles Lancet Oncology Year : 2016

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study

Mahmoud Fekih
  • Function : Author
Thierry Petit
Christelle Levy
Jean-Marc Ferrero
Florence Lerebours
Emmanuelle Charafe-Jauffret
François-Clément Bidard
Patrice Viens
  • Function : Author
Jérôme Lemonnier
  • Function : Author
Jean-Yves Pierga

Domains

Cancer
No file

Dates and versions

hal-03623735 , version 1 (29-03-2022)

Identifiers

Cite

François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, et al.. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncology, 2016, 17 (5), pp.600-611. ⟨10.1016/s1470-2045(16)00011-5⟩. ⟨hal-03623735⟩
35 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More